公开(公告)号：US12178835B2

公开(公告)日：2024-12-31

申请号：US18175409

申请日：2023-02-27

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: C12N5/0735 ,  A61K35/545 ,  A61K45/06 ,  A61P1/16 ,  A61P3/00 ,  A61P3/10 ,  A61P7/04 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P27/02 ,  A61P37/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N15/09

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.

公开(公告)号：US20250144154A1

公开(公告)日：2025-05-08

申请号：US18949799

申请日：2024-11-15

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: A61K35/545 ,  A61K45/06 ,  A61P1/16 ,  A61P3/00 ,  A61P3/10 ,  A61P7/04 ,  A61P9/10 ,  A61P19/02 ,  A61P25/16 ,  A61P27/02 ,  A61P37/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N5/0735 ,  C12N15/09

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.

公开(公告)号：US20230414677A1

公开(公告)日：2023-12-28

申请号：US18175409

申请日：2023-02-27

Applicant: Sinai Health System

Inventor： Andras Nagy ,  Jeffrey Harding ,  Kristina Nagy

IPC: A61K35/545 ,  A61P27/02 ,  A61P7/04 ,  A61P9/10 ,  A61P1/16 ,  A61P3/00 ,  A61P37/06 ,  A61P19/02 ,  A61P3/10 ,  A61P25/16 ,  A61K45/06 ,  C07K14/47 ,  C07K14/52 ,  C07K14/705 ,  C12N5/0735 ,  C12N15/09

CPC classification number: A61K35/545 ,  A61P27/02 ,  A61P7/04 ,  A61P9/10 ,  A61P1/16 ,  A61P3/00 ,  A61P37/06 ,  A61P19/02 ,  A61P3/10 ,  A61P25/16 ,  A61K45/06 ,  C07K14/47 ,  C07K14/521 ,  C07K14/70503 ,  C07K14/70532 ,  C07K14/70575 ,  C12N5/0606 ,  C12N15/09 ,  C12N2510/00

Abstract: A cell genetically modified to comprise at least one mechanism for providing a local immunosuppression at a transplant site when transplanted in an allogeneic host is, and methods for making and using the same is provided. The cell comprises a set of transgenes, each transgene encoding a gene product that is cytoplasmic, membrane bound, or local acting, and whose function is one or more of: to mitigate antigen presenting cell activation and function; to mitigate graft attacking leukocyte activity or cytolytic function; to mitigate macrophage cytolytic function and phagocytosis of allograft cells; to induce apoptosis in graft attacking leukocytes; to mitigate local inflammatory proteins; and to protect against leukocyte-mediated apoptosis.